Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser.
Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
www.ahrq.gov

Table 4. Meta-analyses of Comparisons of Antihypertensive Drugs

Study Description Comparisons Comments
Study
(Population)
(Quality)
Inclusion
Criteria
Number of
Studies
Calcium Antagonists
vs
ACE Inhibitors
vs
Calcium Antagonists
vs
Blood Pressure Trialists, 2000 (72)
(diabetics and nondiabetics)
(good)

Random assignment of patients between anti-hypertensive regimens

Minimum of 1000 p-years in each group

Prespecified outcomes

8 D/beta

CHD 1.121 (1.00 - 1.26)

D/beta

No difference for any outcome

ACEI

1.231 (1.03 - 1.47)
Heterogeneity in trials comparing CA and ACEI
Stroke 0.87 (0.77 - 0.98) 0.98 (0.83 - 1.18)
CHF 1.12 (0.95 - 1.33) 1.22 (1.00 - 1.49)
CVD events 1.02 (0.95 - 1.10) 1.09 (0.99 - 1.20)
Mortality 1.01 (0.92 - 1.11) 0.97 (0.85 - 1.10)
Pahor et al., 2000 (73)
(diabetics and nondiabetics)
(good)
Patients with hypertension; compared CA with another drug;

assessed CVD events; included 100 people or more
9 All other drugs, all participants

MI 1.262 (1.11 - 1.43)
CA, all participants

1.432 (1.15 - 1.76)
All other drugs, diabetics

1.532 (1.01 - 2.31)
Diabetics qualitatively same as all participants, but with higher ORs
Stroke 0.90 (0.80 - 1.02) 1.01 (0.84 - 1.23) 1.37 (0.86 - 2.20)
CHF 1.25 (1.07 - 1.46) 1.24 (1.00 - 1.55) 1.76 (0.97 - 3.21)
CVD events 1.10 (1.02 - 1.18) 1.18 (1.04 - 1.33) 1.44 (1.09 - 1.91)
Mortality 1.03 (0.94 - 1.13) 0.97 (0.83 - 1.13) 1.24 (0.84 - 1.83)
Pahor et al., 2000 (65)
(diabetics only)
(good)
RCT of ACE inhibitor vs other drug for hypertensive diabetics;

≥2 years followup; CVD outcomes

4
ABCD
CAPPP
FACET

UKPDS
(heterogeneity)

NA D/beta or CA

MI 0.373 (0.24 - 0.57)
NA Heterogeneity when UKPDS added in; results are for other 3 trials without

UKPDS
Stroke 0.76(0.48 - 1.22)
CVD events 0.49 (0.36 - 0.67)
Mortality 0.57(0.38 - 0.87)

1 RR (95% CI); values <1 favors calcium antagonists
2 OR (95% CI); OR <1.0 favors calcium antagonists
3 RR (95% CI); RR <1.0 favors ACE inhibitor

Notes: p-years = person - years; first column compares calcium antagonists with diuretic/Bblockers, D/beta = diuretics and/or Bblockers, ACEI = angiotensin converting enzyme inhibitor, CA = calcium antagonists.

Return to Document

 

AHRQ Advancing Excellence in Health Care